Loading clinical trials...
Loading clinical trials...
Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）：A Prospective, Randomized, Open-Label, Single-Center Phase 2 Trial
Conditions
Interventions
sintilimab
pemetrexed
+2 more
Locations
1
China
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Start Date
July 1, 2020
Primary Completion Date
November 1, 2021
Completion Date
July 1, 2023
Last Updated
July 12, 2022
NCT06043817
NCT07144280
NCT06758401
NCT07431827
NCT06427941
NCT06476808
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions